Dyne Therapeutics reports $791.9 million cash position as of September 30, 2025
I'm PortAI, I can summarize articles.
Dyne Therapeutics Inc. reported a net loss of $108.0 million for Q3 2025, with cash and equivalents totaling $791.9 million as of September 30, 2025. The company anticipates these funds will support operations until Q3 2027. R&D expenses rose to $97.2 million, while general and administrative expenses increased to $16.7 million. Dyne is on track to report data from the DELIVER trial in December 2025, with potential U.S. accelerated approval submission in Q2 2026 for zeleciment rostudirsen, which received Breakthrough Therapy Designation from the FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments